Skip to main content
. 2013 Sep 30;98(12):4752–4758. doi: 10.1210/jc.2013-2182

Figure 5.

Figure 5.

Diagnostic performance of an end of fast proinsulin >22 pmol/L or equivalent across three nonoverlapping series of NIH patients evaluated with a supervised fast. These data represent 176 patients with insulin-producing tumors and 50 control subjects. (Proinsulin prior to 1995 was not directly measured; values obtained using the indirect proinsulin assay were converted to concentrations using a correlation analysis between the indirect and direct proinsulin assays.)